Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05020678Phase 1Active Not Recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Role: lead

NCT06733935Phase 1Recruiting

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Role: lead

NCT06557265Phase 1Recruiting

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

Role: lead

NCT04623944Phase 1Active Not Recruiting

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Role: lead

All 4 trials loaded